NYC firm to help Company generate awareness for its life saving 3D bioprinting technology as it prepares to launch its Regulation A+ equity crowdfunding campaign
CHICAGO – November, 30, 2017 – BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has retained FischTank Marketing and PR, a New York City-based firm, as its Agency of Record to conduct national and trade media outreach, generate awareness for its upcoming Regulation A+ equity crowdfunding campaign, and advise on all marketing and communications functions.
The relationship was established to support the Company as it seeks to raise its profile ahead of its equity fund raise in early 2018, and as it develops messaging and marketing strategy to generate awareness within the medical community. FischTank will seek to increase BIOLIFE4D’s overall exposure, develop and maintain external communications, and hone marketing strategies.
“As we continue to develop our technology and prepare for our Regulation A+ raise in early 2018, we felt it was crucial to establish a strong and consistent marketing and communications strategy, for both potential investors and key partners within the medical community,” said Steven Morris, CEO, BIOLIFE4D. “FischTank has the depth of experience we are looking for, having led biotech startups through this process before, with showcased results. We look forward to their guidance during this important time for our Company.”
BIOLIFE4D is a biotech startup focused on making human organ replacement commonplace globally using an approach that combines recent breakthroughs in regenerative medicine, stem cell biology, 3D printing techniques, and computing technology.
“What BIOLIFE4D is doing from an innovation standpoint is remarkable and something we are excited to be a part of – literally giving people the gift of time,” said Matthew Bretzius, President, FischTank Marketing and PR. “We look forward to working with the team to develop a sound messaging strategy and to generate awareness for the technology and the RegA+ fund raise, but also for general heart health.”
BBIOLIFE4D has filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ equity crowdfunding rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. The “Reg A+” rules, outlined under the 2012 Jumpstart Our Business Startups (JOBS) Act, allow companies to raise up to $50 million in equity from non-accredited investors and others.
To learn more about BIOLIFE4D and to express interest in investing visit https://biolife4d.com/invest/.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), Facebook, LinkedIn, and Instagram.
Although you are currently able to express your interest in investing, BIOLIFE4D Corporation is not yet accepting investments. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. If you indicate interest, your indication of interest involves no obligation or commitment of any kind.